Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Epigenetic regulator UHRF1 orchestrates proinflammatory gene expression in rheumatoid arthritis in a suppressive manner
Noritaka Saeki, … , Shu Takeda, Yuuki Imai
Noritaka Saeki, … , Shu Takeda, Yuuki Imai
Published April 26, 2022
Citation Information: J Clin Invest. 2022;132(11):e150533. https://doi.org/10.1172/JCI150533.
View: Text | PDF
Research Article Autoimmunity Bone biology

Epigenetic regulator UHRF1 orchestrates proinflammatory gene expression in rheumatoid arthritis in a suppressive manner

  • Text
  • PDF
Abstract

Rheumatoid arthritis (RA) is characterized by chronic synovial inflammation with aberrant epigenetic alterations, eventually leading to joint destruction. However, the epigenetic regulatory mechanisms underlying RA pathogenesis remain largely unknown. Here, we showed that ubiquitin-like containing PHD and RING finger domains 1 (UHRF1) is a central epigenetic regulator that orchestrates multiple pathogeneses in RA in a suppressive manner. UHRF1 expression was remarkably upregulated in synovial fibroblasts (SFs) from arthritis model mice and patients with RA. Mice with SF-specific Uhrf1 conditional knockout showed more severe arthritic phenotypes than littermate controls. Uhrf1-deficient SFs also exhibited enhanced apoptosis resistance and upregulated expression of several cytokines, including Ccl20. In patients with RA, DAS28, CRP, and Th17 accumulation and apoptosis resistance were negatively correlated with UHRF1 expression in synovium. Finally, Ryuvidine administration stabilized UHRF1 ameliorated arthritis pathogeneses in a mouse model of RA. This study demonstrated that UHRF1 expressed in RA SFs can contribute to negative feedback mechanisms that suppress multiple pathogenic events in arthritis, suggesting that targeting UHRF1 could be one of the therapeutic strategies for RA.

Authors

Noritaka Saeki, Kazuki Inoue, Maky Ideta-Otsuka, Kunihiko Watamori, Shinichi Mizuki, Katsuto Takenaka, Katsuhide Igarashi, Hiromasa Miura, Shu Takeda, Yuuki Imai

×

Figure 6

UHRF1 expression is negatively correlated with several RA pathogeneses.

Options: View larger image (or click on image) Download as PowerPoint
UHRF1 expression is negatively correlated with several RA pathogeneses.
...
(A) Expression levels of UHRF1 and DNMTs (DNMT1, DNMT3A, and DNMT3B) mRNA in synovium obtained from patients with OA (n = 32) and RA (n = 30). (B) Spearman’s correlation between UHRF1 mRNA expression in RA synovium (n = 30) and disease activity score 28-CRP (DAS28) as well as levels of C-reactive protein (CRP) and age. (C) Correlation of UHRF1 expression in RA synovium with 6-month response to DMARD treatment measured by ΔDAS28-CRP (https://peac.hpc.qmul.ac.uk/). (D) Top, Western blot analysis of OA synovium (n = 5) and RA synovium (n = 5). Bottom, quantification of relative UHRF1 protein levels. (E) H&E staining and immunofluorescence staining for UHRF1 (red); PDPN, FAP, CD45 (green); and DAPI (blue) in specimens from multiple patients with RA (P1–P4). Scale bar: 100 μm. Arrow and arrowhead indicate UHRF1+ cells in cells positive for SF markers PDPN and FAP and leukocyte marker CD45, respectively. (F) Quantification of UHRF1+ cell number in CD45+ cells and CD45– cells among total UHRF1+ cells (n = 19). (G) Spearman’s correlation between DAS28 and number of UHRF1+ cells per tissue area (n = 19). Mean ± SD is shown. *P < 0.05 and **P < 0.01 by Mann-Whitney U test in A and D, and by Wilcoxon signed-rank test in F. All data were obtained from 5–32 independent experiments.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts